Sun Pharmaceutical Industries’ wholly owned subsidiary -- Sun Pharma Canada has launched WINLEVI (clascoterone cream 1% w/w), a Novel Topical Treatment for Acne in Canada. WINLEVI is the first and only androgen receptor inhibitor indicated for the topical treatment of acne vulgaris (acne) in patients 12 years of age and older.
WINLEVI works differently from any other topical acne treatment. Instead of a topical approach to acne treatment that focuses on follicular hyperkeratinization, reducing inflammation or exerting antibacterial effects, WINLEVI is thought to reduce the effects of acne hormones on skin by disrupting the androgen cascade. While the exact way that WINLEVI works is unknown, it aims to inhibit the effects of androgen receptors in cells of the sebaceous glands (oil-producing glands in the skin) to help reduce sebum (oil) production and inflammatory cytokines.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1827.00 |
Dr. Reddys Lab | 1371.60 |
Cipla | 1491.70 |
Lupin | 2250.40 |
Zydus Lifesciences | 1009.40 |
View more.. |